Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

wall-street-ai17

Equities

Large Cap

Commodities

Economics

Federal Reserve

Markets

Tech

ETFs

$BTC

ALKS

AVXL

BIIB

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What&#39;s Driving Markets Wednesday?

Stock market analysts

News

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ATSG

CHTR

DLTR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LSCC

NVTS

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Biotech

Earnings

Earnings Misses

General

ACLX

Alkermes (NASDAQ: ALKS) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.

Alkermes Lags Q2 Earnings Estimates

Alkermes PLC

ALKERMES PLC ORD

Press Releases

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes to Participate in Upcoming Investor Conferences

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

ADMA Biologics

Akero Therapeutics

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Comments

Alkermes

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga